Different Glaucoma Treatments Effect on Intraocular Pressure Fluctuation With Postural Change in Eyes With Open-angle Glaucoma

Sponsor
Meir Medical Center (Other)
Overall Status
Unknown status
CT.gov ID
NCT02868502
Collaborator
(none)
150
11

Study Details

Study Description

Brief Summary

The purpose of this study is to investigate the effect of trabeculectomy, glaucoma drainage devices, cyclophotocoagulation and ocular hypotensive eye-drops on IOP elevation with postural change from the sitting to supine positions in eyes with open-angle glaucoma.

Patients will be assigned to the different study groups according to their past ocular history. Interventions are similar to all study group and no medical therapy alteration will be made.

Condition or Disease Intervention/Treatment Phase
  • Device: Goldmann tonometer
  • Device: Pneumatonometer
  • Device: Tonopen XL
  • Device: ICare rebound tonometer

Detailed Description

Visual impairment and blindness due to chronic progressive optic neuropathy developing from glaucoma are major health problems worldwide.

Glaucoma is a progressive, potentially blinding disease, in which the only modifiable risk factor in intraocular pressure. In a significant proportion of patients, the disease progresses despite apparent IOP control(1-3).

One factor which may explain some of this discrepancy is a fluctuation of the IOP during the day, which may be missed in a single visit to the ophthalmologist(4). Although this fluctuation depends to some degree on daily biologic rhythms and the specific type of glaucoma, a constant significant factor responsible for this effect is the IOP-dependent changes of body posture, from sitting or standing to lying down(5). Older studies have shown IOP postural changes in the range of 4-6 mmHg(6-8). Seeing how a typical patient may spend as much as a third of his life in the supine position, knowledge of IOP in this position, and its control, are of great importance in decreasing the chance for irreversible optic nerve damage.

Several studies of Liu JH(9-11) have investigated the effect of hypotensive drops on nocturnal IOP. While prostaglandin analogues (PGA) and carbonic anhydrase inhibitors (CAI) seemed to have a significant nocturnal IOP lowering effect, the effect seen with beta blockers and alpha agonists was minimal. Mansouri et al.(12) recently showed that PGA seem to flatten the IOP-related increase when moving from the sitting to the supine position at nocturnal period, without effecting other circadian IOP-related patterns.

Hirooka Kazuyuki investigated the effect of trabeculectomy on the IOP fluctuations caused by postural changes(13-14). He showed that successful trabeculectomy, which didn't require needling, have significantly decreased the posture-induced IOP changes to less than 3 mmHg.

To the best of our knowledge there is no data regarding the effect of glaucoma drainage devices and cyclophotocoagulation on supine IOP.

The purpose of this study is to investigate the effect of different IOP lowering methods, including trabeculectomy, glaucoma drainage devices, cyclophotocoagulation and ocular hypotensive eye-drops on IOP with postural change from the sitting to supine positions in eyes with open-angle glaucoma.

Study Design

Study Type:
Observational
Anticipated Enrollment :
150 participants
Observational Model:
Case-Control
Time Perspective:
Cross-Sectional
Official Title:
The Effect of Trabeculectomy, Glaucoma Drainage Device, Cyclophotocoagulation, and Ocular Hypotensive Eye-drops on Intraocular Pressure Fluctuation With Postural Change in Eyes With Open-angle Glaucoma
Study Start Date :
Sep 1, 2016
Anticipated Primary Completion Date :
Aug 1, 2017
Anticipated Study Completion Date :
Aug 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Trabeculectomy

Subjects with OAG s/p Trabeculectomy. IOP measurement in different positions.

Device: Goldmann tonometer
IOP measurement in the sitting position and lateral decubitus

Device: Pneumatonometer
IOP measurement in the sitting position and lateral decubitus

Device: Tonopen XL
IOP measurement in the sitting position and lateral decubitus

Device: ICare rebound tonometer
IOP measurement in the sitting position and lateral decubitus

Ahmed Glaucoma Valve implantation

Subjects with OAG s/p Ahmed valve implantation. IOP measurement in different positions.

Device: Goldmann tonometer
IOP measurement in the sitting position and lateral decubitus

Device: Pneumatonometer
IOP measurement in the sitting position and lateral decubitus

Device: Tonopen XL
IOP measurement in the sitting position and lateral decubitus

Device: ICare rebound tonometer
IOP measurement in the sitting position and lateral decubitus

Cyclophotocoagulation

Subjects with OAG s/p Cyclophotocoagulation. IOP measurement in different positions.

Device: Goldmann tonometer
IOP measurement in the sitting position and lateral decubitus

Device: Pneumatonometer
IOP measurement in the sitting position and lateral decubitus

Device: Tonopen XL
IOP measurement in the sitting position and lateral decubitus

Device: ICare rebound tonometer
IOP measurement in the sitting position and lateral decubitus

Ocular hypotensive eye drops

Subjects with OAG treated with ocular hypotensive eye drops and no ocular surgical hypotensive treatments. IOP measurement in different positions.

Device: Goldmann tonometer
IOP measurement in the sitting position and lateral decubitus

Device: Pneumatonometer
IOP measurement in the sitting position and lateral decubitus

Device: Tonopen XL
IOP measurement in the sitting position and lateral decubitus

Device: ICare rebound tonometer
IOP measurement in the sitting position and lateral decubitus

Ocular Hypertension

Subjects with no evidence of glaucomatous damage, but with IOP measurements above 21 mmHg.. IOP measurement in different positions.

Device: Goldmann tonometer
IOP measurement in the sitting position and lateral decubitus

Device: Pneumatonometer
IOP measurement in the sitting position and lateral decubitus

Device: Tonopen XL
IOP measurement in the sitting position and lateral decubitus

Device: ICare rebound tonometer
IOP measurement in the sitting position and lateral decubitus

Control

Subjects with healthy eyes, apart for refraction errors, post cataract surgery, strabismus or amblyopia. IOP measurement in different positions.

Device: Goldmann tonometer
IOP measurement in the sitting position and lateral decubitus

Device: Pneumatonometer
IOP measurement in the sitting position and lateral decubitus

Device: Tonopen XL
IOP measurement in the sitting position and lateral decubitus

Device: ICare rebound tonometer
IOP measurement in the sitting position and lateral decubitus

Outcome Measures

Primary Outcome Measures

  1. Measurements of Intra Ocular Pressure Fluctuation with Postural Change in Eyes with Open-angle Glaucoma and Ocular Hypertension, compared to healthy subjects [Change from baseline 5 minutes following position change]

    Interventions are similar for all study groups: The subject will be instructed to stay in a sitting position for 5 minutes. A topical anesthetic eye drop (oxybuprocaine hydrochloride 0.4%) will then be installed in the study eye (necessary procedure made in all IOP examinations as a regular procedure) and the IOP will be measured, in the following order by 4 tonometers: Goldmann tonometer, Pneumatonometer, Tonopen XL, ICare rebound tonometer. The subject will then lie supine for 5 minutes, afterwards will turn to the lateral decubitus position and IOP will be measured again using the same tonometers in the same manner. The difference between IOP in the sitting and lying body positions will be assessed and compared to the control group.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 95 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • OAG patients

  • Ocular Hypertension (OHT) patients

  • Healthy subjects, without any ocular pathology (except for refraction errors, past cataract surgery, strabismus or amblyopia).

Exclusion Criteria:
  • Other intraocular surgeries within the past 3 months

  • Illness effecting episcleral venous pressure, such as superior vena cava syndrome, thyroid eye disease, orbital masses

  • Patients who are unable to maintain supine position for 15 minutes

  • Corneal abnormalities: epithelial pathologies, corneal infection, corneal erosions, corneal scars, keratoconus, S/P corneal transplantation (lamellar/full thickness)

  • Hypersensitivity to oxybuprocaine hydrochloride

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Meir Medical Center

Investigators

  • Principal Investigator: Avner Belkin, M.D, Meir Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Avner Belkin, MD, Meir Medical Center
ClinicalTrials.gov Identifier:
NCT02868502
Other Study ID Numbers:
  • MMC-0026-16
First Posted:
Aug 16, 2016
Last Update Posted:
Aug 16, 2016
Last Verified:
Aug 1, 2016
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Keywords provided by Avner Belkin, MD, Meir Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 16, 2016